Challenging the pipeline

Peter Loskill; Rhiannon N Hardwick; Adrian Roth

doi:10.1016/j.stemcr.2021.08.004

Challenging the pipeline

Stem Cell Reports. 2021 Sep 14;16(9):2033-2037. doi: 10.1016/j.stemcr.2021.08.004.

Authors

Peter Loskill¹, Rhiannon N Hardwick², Adrian Roth³

Affiliations

¹ Department of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen, Germany. Electronic address: [email protected].
² Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA.
³ Personalized Healthcare Safety Interface, Product Development Safety, Roche Innovation Centre Basel, Basel, Switzerland.

Abstract

This commentary presents a thought experiment seeking to answer the key question: "If you were to put aside all the traditional drug discovery processes and start a new drug discovery program that places the highest priority on human and disease-relevant models throughout the entire process, how could it be done?"

Publication types

Letter

MeSH terms

Cell Culture Techniques
Drug Discovery / methods*
Drug Evaluation, Preclinical / methods
Humans
Stem Cells / cytology
Stem Cells / drug effects*
Stem Cells / metabolism*